|
|
|
|
| LEADER |
02926 am a22004693u 4500 |
| 001 |
105498 |
| 042 |
|
|
|a dc
|
| 100 |
1 |
0 |
|a Grant, Robert A.
|e author
|
| 100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Biological Engineering
|e contributor
|
| 100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Biology
|e contributor
|
| 100 |
1 |
0 |
|a Koch Institute for Integrative Cancer Research at MIT
|e contributor
|
| 100 |
1 |
0 |
|a Cannell, Ian Gordon
|e contributor
|
| 100 |
1 |
0 |
|a Merrick, Karl Andrew
|e contributor
|
| 100 |
1 |
0 |
|a Morandell, Sandra M.
|e contributor
|
| 100 |
1 |
0 |
|a Braun, Christian Jorg
|e contributor
|
| 100 |
1 |
0 |
|a Grant, Robert A
|e contributor
|
| 100 |
1 |
0 |
|a Cameron, Eleanor Ruth
|e contributor
|
| 100 |
1 |
0 |
|a Hemann, Michael
|e contributor
|
| 100 |
1 |
0 |
|a Yaffe, Michael B
|e contributor
|
| 700 |
1 |
0 |
|a Tsao, Ming-Sound
|e author
|
| 700 |
1 |
0 |
|a Cannell, Ian Gordon
|e author
|
| 700 |
1 |
0 |
|a Merrick, Karl Andrew
|e author
|
| 700 |
1 |
0 |
|a Morandell, Sandra M.
|e author
|
| 700 |
1 |
0 |
|a Grant, Robert A
|e author
|
| 700 |
1 |
0 |
|a Cameron, Eleanor Ruth
|e author
|
| 700 |
1 |
0 |
|a Hemann, Michael
|e author
|
| 700 |
1 |
0 |
|a Yaffe, Michael B
|e author
|
| 700 |
1 |
0 |
|a Braun, Christian Joerg
|e author
|
| 245 |
0 |
0 |
|a A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy
|
| 260 |
|
|
|b Elsevier,
|c 2016-12-01T19:41:32Z.
|
| 856 |
|
|
|z Get fulltext
|u http://hdl.handle.net/1721.1/105498
|
| 520 |
|
|
|a In normal cells p53 is activated by DNA damage checkpoint kinases to simultaneously control the G1/S and G2/M cell cycle checkpoints through transcriptional induction of p21[superscript cip1] and Gadd45α. In p53 mutant tumors, cell cycle checkpoints are rewired, leading to dependency on the p38/MK2 pathway to survive DNA-damaging chemotherapy. Here we show that the RNA binding protein hnRNPA0 is the "successor" to p53 for checkpoint control. Like p53, hnRNPA0 is activated by a checkpoint kinase (MK2) and simultaneously controls both cell cycle checkpoints through distinct target mRNAs, but unlike p53 this is through the post-transcriptional stabilization of p27[superscript Kip1] and Gadd45α mRNAs. This pathway drives cisplatin resistance in lung cancer demonstrating the importance of post-transcriptional RNA control to chemotherapy response.
|
| 520 |
|
|
|a Austrian Science Fund (Grant J 2900-B21)
|
| 520 |
|
|
|a German Cancer Aid (Mildred-Scheel Fellowship)
|
| 520 |
|
|
|a Damon Runyon Cancer Research Foundation (Grant DRG 2127-12)
|
| 520 |
|
|
|a National Institutes of Health (U.S.) (Grants ES015339, GM60594, GM59281 and CA112967)
|
| 520 |
|
|
|a Anna Fuller Fund
|
| 520 |
|
|
|a David H. Koch Institute for Integrative Cancer Research at MIT (Core Grant P30-CA14051)
|
| 520 |
|
|
|a Massachusetts Institute of Technology. Center for Environmental Health Sciences (Core Grant ES-002109)
|
| 546 |
|
|
|a en_US
|
| 655 |
7 |
|
|a Article
|
| 773 |
|
|
|t Cancer Cell
|
